Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. September 2024 04:30 ET | Quelle: Curium US LLC

Curium Anuncia Que PYLCLARI®, un Innovador Trazador PET 18F-PSMA Indicado en Pacientes Con Cáncer De Próstata, Ya Está Disponible en España

PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...
10. September 2024 04:30 ET | Quelle: Curium

Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain

CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN
30. Mai 2024 03:00 ET | Quelle: Curium

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer

first doses of PYLCLARI in France for prostate cancer patients
08. April 2024 03:25 ET | Quelle: Curium

Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol

CURIUM AGREEMENT TO ACQUIRE ECZACIBAŞI-MONROL
02. März 2023 07:44 ET | Quelle: Curium

Innovation and Growing Demand for Nuclear Medicine Drives Curium Expansion and 10-Year Commitment to St. Louis, MO

Renaissance in nuclear medicine to attract top St. Louis talentNorth America Headquarters to call Westport Plaza home for the next 10 yearsOver 100 new jobs in the next 3 years ST. LOUIS, March 02,...